CA2527726A1 - De-immunized anti-cd3 antibody - Google Patents

De-immunized anti-cd3 antibody Download PDF

Info

Publication number
CA2527726A1
CA2527726A1 CA002527726A CA2527726A CA2527726A1 CA 2527726 A1 CA2527726 A1 CA 2527726A1 CA 002527726 A CA002527726 A CA 002527726A CA 2527726 A CA2527726 A CA 2527726A CA 2527726 A1 CA2527726 A1 CA 2527726A1
Authority
CA
Canada
Prior art keywords
antibody
immunized
chain variable
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002527726A
Other languages
English (en)
French (fr)
Inventor
Russell P. Rother
Susan Faas Mcknight
Dayang Wu
Francis J. Carr
Anita Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck KGaA
Alexion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2527726A1 publication Critical patent/CA2527726A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002527726A 2003-06-02 2004-05-28 De-immunized anti-cd3 antibody Abandoned CA2527726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47515503P 2003-06-02 2003-06-02
US60/475,155 2003-06-02
PCT/US2004/017219 WO2004108158A1 (en) 2003-06-02 2004-05-28 De-immunized anti-cd3 antibody

Publications (1)

Publication Number Publication Date
CA2527726A1 true CA2527726A1 (en) 2004-12-16

Family

ID=33511652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002527726A Abandoned CA2527726A1 (en) 2003-06-02 2004-05-28 De-immunized anti-cd3 antibody

Country Status (7)

Country Link
US (1) US20070292416A1 (https=)
EP (1) EP1658095A4 (https=)
JP (1) JP2006526414A (https=)
CN (1) CN1822857A (https=)
AU (1) AU2004245038A1 (https=)
CA (1) CA2527726A1 (https=)
WO (1) WO2004108158A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US8530629B2 (en) * 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
CA2780153A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
JP2013514788A (ja) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
JP6038121B2 (ja) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
EP2718326B1 (en) 2011-06-13 2020-08-19 CSL Limited Antibodies against g-csfr and uses thereof
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
WO2014117220A1 (en) 2013-02-01 2014-08-07 Transbio Ltd Anti-cd83 antibodies and use thereof
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
RU2718054C2 (ru) 2013-11-28 2020-03-30 СиЭсЭл ЛИМИТЕД Способ лечения нефропатии
WO2015089585A1 (en) 2013-12-18 2015-06-25 Csl Limited Method of treating wounds
EP3209695A4 (en) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Cd83 binding proteins and uses thereof
AU2015336946A1 (en) 2014-10-23 2017-04-13 La Trobe University Fn14-binding proteins and uses thereof
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
KR102654033B1 (ko) * 2014-12-08 2024-04-02 1글로브 바이오메디칼 씨오., 엘티디. 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP4512469A3 (en) 2017-09-11 2025-05-21 Monash University Binding proteins to the human thrombin receptor, par4
JP7793287B2 (ja) 2017-10-18 2026-01-05 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
JP7542438B2 (ja) * 2017-11-21 2024-08-30 ノバルティス アーゲー 腫瘍関連抗原に対する三重特異性結合分子及びその使用
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
CA3100071A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
AR115730A1 (es) 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
US20230128499A1 (en) * 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4182475A2 (en) 2020-07-17 2023-05-24 Onena Medicines S.L. Antibodies against lefty proteins
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
US20260061078A1 (en) 2022-08-31 2026-03-05 Universität Zürich Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Also Published As

Publication number Publication date
JP2006526414A (ja) 2006-11-24
US20070292416A1 (en) 2007-12-20
WO2004108158A1 (en) 2004-12-16
EP1658095A1 (en) 2006-05-24
EP1658095A4 (en) 2006-06-14
AU2004245038A1 (en) 2004-12-16
CN1822857A (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
US20070292416A1 (en) De-Immunized Anti-Cd3 Antibody
EP1383785B1 (en) Recombinant tumor specific antibody and use thereof
JP3653093B2 (ja) 人化抗体
EP4582449A1 (en) Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof
CN106046159B (zh) Cd37结合分子及其免疫缀合物
US7332582B2 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JP3803790B2 (ja) 新規なダイアボディ型二重特異性抗体
EP3442567B1 (en) Anti-psma antibodies and use thereof
JP2024026132A (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
EP2281845A1 (en) Stable polyvalent antibody
EP4112647A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
CN111349163B (zh) 针对cd123的单克隆抗体
JP6254522B2 (ja) ヒト化抗ｃｄ５２抗体
CN115087673A (zh) 结合il4r的抗体及其用途
EP4039702A1 (en) Anti-b7-h3 antibody and application thereof
TW202246340A (zh) 抗ctla-4抗體及其應用
WO2025021027A1 (zh) 靶向人源cd7的抗体或其抗原结合片段及其应用
KR20230166096A (ko) Cldn18.2 항원 결합 단백질 및 이의 적용
CN118667003A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
EP4406970A1 (en) Monoclonal antibody targeting tigit
MXPA06009759A (es) Codocito para trastornos por linfocitos b.
CN114478788B (zh) 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
JP2005333993A (ja) 新規なダイアボディ型二重特異性抗体
EP4219553A1 (en) Anti-tigit antibody and double antibody and their application
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued